Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Auxilium Pharma, GlaxoSmithKline Sign Agreement For Co-promotion Of Testim 1%

Auxilium Pharmaceuticals, Inc. (AUXL: Quote) and GlaxoSmithKline LLC, the U.S. subsidiary of GlaxoSmithKline plc (GSK: Quote, GSK.L), announced that they have entered into an agreement for the co-promotion of Testim 1% (testosterone gel), which is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of testosterone.

As per the agreement terms, Auxilium granted GSK the exclusive right to co-promote the sale of Testim with Auxilium in the U.S. through September 30, 2015. GSK will promote Testim using a sizeable established field sales force which has relationships with current Testosterone Replacement Therapy prescribers, particularly primary care physicians, in the U.S.

Both the companies have agreed on a baseline revenue forecast for Testim through September 30, 2015, and GSK will be compensated to the extent that Testim net sales exceed this baseline. In addition, in certain circumstances, Auxilium will pay GSK specified tail payments following the term of the agreement. The GSK sales force is expected to begin promoting Testim to physicians early in the third quarter 2012.

In a separate press release, Auxilium Pharma said it is raising its full year 2012 revenue guidance to a range of $293 million to $315 million from prior forecast of $283 million- $305 million.

The company also said it is reducing its full-year guidance for net loss to a range of $5 to $10 million from the previous range of $5 to $15 million.

Analysts polled by Thomson Reuters expect the company to report loss of $0.27 per share, on revenues of $299.16 million. Analysts' estimates typically exclude special items.

"As a result of this morning's announcement concerning the Testim U.S. co-promotion agreement, we are increasing Testim revenue guidance and trimming net loss guidance for 2012," said Jim Fickenscher, Chief Financial Officer of Auxilium. "While we have not changed our previously stated guidance for Selling, General & Administrative expense, it is likely that we will be near the top end of the range."

Register
To receive FREE breaking news email alerts for Auxilium Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Stocks have fluctuated over the course of the trading day on Thursday, as traders continue to digest yesterday's monetary policy announcement from the Federal Reserve as well as better than expected third quarter GDP data. Hundreds of protesters stormed Burkina Faso's parliament on Thursday and set fire to the building, preventing the lawmakers from considering a bill to extend the president's 27-year rule. Security forces opened fire on protesters, as they looted computers and televisions in the National Assembly, news agencies reported. The angry crowd then marched towards the President's office, before they were U.S. economic activity increased by more than expected in the third quarter of 2014, according to a report released by the Commerce Department on Thursday. The Commerce Department said GDP increased by 3.5 percent in the third quarter compared to 3.0 percent growth expected by economists.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.